CClinicalTrials.gg
CompletedNCT04463862Updated Jun 25, 2021

COVID - AirPollution

An observational study in COVID-19 Confirmed Cases and COVID-19 Mortality, sponsored by University Hospital, Strasbourg, France. Completed at 8 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-06-25.

Sponsored by University Hospital, Strasbourg, France · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
660
Ages
50 Years and older
Sex
All
01

Study summary

Epidemiological data have related particulate matter (PM), nitrogen dioxide (NO2) and ozone (O3) to COVID-19 morbidity and mortality at the population level. Air pollution may be related to an increase in the COVID-19 severity and lethality through its impact on chronic diseases such as cardiovascular and respiratory diseases and diabetes that are also the main comorbidities associated with COVID-19. Epidemiological studies using individual data are needed to provide more precise estimate of the association between air pollution exposure and COVID-19. In this multicenter prospective study, the investigators will analyze the number of deaths in COVID-19 confirmed cases in geriatric patients according to long-term exposure to air pollution, taking into account confounders such as diabetes, hypertension, age, and BMI. Exposure to air pollution will be estimated as the mean concentration of air pollutants at the residential address during the previous two years. In addition, the investigators will explore the relationship between short-term variations in air pollutants, relative humidity, temperature, UV radiations, pollen and the occurrence of COVID-19.

02

Conditions studied

  • COVID-19 Confirmed Cases
  • COVID-19 Mortality

Browse trials for

Keywords

  • Air pollution
  • COVID-19
  • Respiratory viral diseases
  • PM- NO2-Ozone
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 660 is above the median of 261 across 3,136 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted in geriatric departments between 2020/01/01 to 2020/06/01

Inclusion criteria

  • Patient over 60 years old (or dementia patient over 50 years old)
  • Patient hospitalized in a geriatric department over the period from 2020/01/01 to 2020/06/01
  • Patient who underwent RT-PCR SARS-CoV-2
  • Patient (or trusted person/ legal guardian/curator, if applicable) who has given consent to the re-use of his/her data (patient data) for research purposes

Exclusion criteria

Exclusion Criteria:

None

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
660 participants (actual)
Target follow-up
6 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. COVID-19 related-mortality

    Association between COVID-19 related-mortality and air pollutants concentrations estimated at the residential address of geriatric patients during the last 2 years ( from 2018/01/01 to 2019/12/31)

    Time frame: COVID-19 mortality between 2020/01/01 and 2020/06/01

Secondary outcomes

  1. COVID-19 confirmed cases

    Association between short- term variations in air pollutants, temperature, humidity, UV, pollens and the occurrence of COVID-19 confirmed cases. Short-term variations are defined as changes in air pollutants concentrations, temperature, humidity and pollen during the 20 days preceding the hospitalization.

    Time frame: COVID-19 confirmed cases between 2020/01/01 and 2020/06/01

07

Study locations

8 sites
  • Unité de neurologie-gériatrie, Hôpital Erasme, Cliniques Universitaires de Bruxelles
    Bruxelles, 1090, Belgium
  • Unité de soins palliatifs gériatriques, Centre Hospitalier Départemental de Bischwiller
    Bischwiller, 67241, France
  • Service de Gériatrie, Centre Hospitalier Départemental de Vendée
    La Roche Sur Yon, 85925, France
  • Service de médecine aigüe gériatrique, Hôpital Nord Laennec, Hôpitaux Universitaires de Nantes
    Nantes, 44093, France
  • Service de Gériatrie, Hôpitaux Bichat et Bretonnaux, Assistance Publique des Hôpitaux de Paris
    Paris, 75018, France
  • Service de Médecine Interne et Gériatrie, Hôpitaux Universitaires de Reims
    Reims, 51100, France
  • Service de Gériatrie, Hôpital de la Robertsau, Hôpitaux Universitaires de Strasbourg
    Strasbourg, 67000, France
  • Service de médecine gériatrique, Hôpitaux Universitaires de Tours
    Tours, 37044, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04463862
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Jul 9, 2020
Start date
Jun 4, 2020
Primary completion
Jun 1, 2021
Completion
Jun 1, 2021
Last update
Jun 25, 2021

Study contacts

Frédéric BLANC, MD
principal investigator · Hôpitaux Universitaires de Strasbourg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion